This technology describes a strategy for the synthesis of novel fluorescent thallium indicator dyes, which are useful for high throughput testing of potassium-dependent ion channel or transporter activity.
REDCap (Research Electronic Data Capture) is a secure web application for building and managing online surveys and databases. Despite its broad potential application, the primary function is for Electronic Data Capture, specifi cally for Clinical Trial Management solutions. REDCap is a globally implemented platform at over 450 institutional partners from CTSA, GCRC, RCMI and other institutions in 49 countries. The REDCap application allows users to build and manage online surveys and databases quickly and securely, and is currently in production use or development build-status for more than 44,000 projects with over 59,000 users spanning numerous research focus areas across the consortium.
The invention is a device which permits the direct quantification of leachable organic constituents from within solid materials. It is expected that the device will be used in landfills and in other environments where measurements are central to the evaluation of the environmental compatibility of solid materials (e.g., sediments, soils, solidified waste forms) containing organic constituents that have the potential to degrade water resources of to be taken up by biota and the food chain. The invention is designed to simplify current difficulties in assessing leaching of organic constituents with low aqueous solubility.
Bright minds at Vanderbilt University have unveiled a breakthrough technology that could bring sophisticated biomarker diagnostics to the developing world. The point-of-care diagnostic is designed to be used in the field; no specialized equipment, expertise, or white lab coats are required. The diagnostic is based upon the ingenous observation that evaporating liquid droplets leave behind a characteristic ring pattern, which may be familiar to our readers in the form of a coffee-ring stain.
The OLINDA/EXM® personal computer code performs dose calculations and kinetic modeling for radiopharmaceuticals (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). OLINDA® calculates radiation doses to different organs of the body from systemically administered radiopharmaceuticals and performs regression analysis on user-supplied biokinetic data to support such calculations for nuclear medicine drugs. These calculations are used to perform risk/benefit evaluations of the use of such pharmaceuticals in diagnostic and therapeutic applications in nuclear medicine. The technology employs a number of standard body models for adults, children, pregnant women and others, that are widely accepted and used in the internal dose community. The calculations are useful to pharmaceutical industry developers, nuclear medicine professionals, educators, regulators, researchers and others who study the accepted radiation doses that should be delivered when radioactive drugs are given to patients or research subjects.
Heart valve disease is the 3rd most prevalent source of cardiovascular disease, leading to approximately 20,000 deaths per year in the U.S. alone. Moreover, there are an estimated 41,000 mitral valve procedures performed in the U.S. each year. The only effective, long-term treatment for mitral valve disease is open-chest valve replacement surgery, which is highly undesirable for elderly patients. Thus, there is a pressing need to develop novel percutaneous strategies for treatment that will reduce the number of open-chest surgeries. David Merryman and colleagues have developed a new, combined catheter that uses cryo temperatures to adhere to moving mitral valve leaflets and radiofrequency ablation to alter the compliance of the leaflet tissue to prevent prolapse and regurgitation.
This technology enables the delivery of biological molecules into the interior of a cell. Such a delivery mechanism could be utilized in a variety of therapies including peptide, gene transfer and/or antisense therapy.
This invention relates generally to a method of identifying an individual having an increased susceptibility to developing Familial Primary Pulmonary Hypertension (FPPH), as well as to a method for diagnosing an individual suffering from FPPH. The invention also relates to a method of identifying an individual having an increased susceptibility to developing (non-familial) Primary Pulmonary Hypertension (PPH), as well as to a method for diagnosing an individual suffering from PPH.
This technology facilitates the discovery and design of novel agents for either repelling or otherwise controlling insects that have important economic or medical significance. In particular, mosquitoes are responsible for transmitting a number of diseases, including malaria, West Nile, dengue and yellow fevers. The Zwiebel laboratory has identified human odorants and the protein receptors in mosquitoes that allow female mosquitoes to identify their hosts when they need blood to satisfy their reproductive needs. With funding from the Gates Foundation's Grand Challenge in Global Health initiative, the Zwiebel laboratory, along with collaborators at Yale, Wageningen University in the Netherlands, and researchers in Africa, developed biological and behavioral assays to screen and test numerous agents as potential repellants and attractants for the Anopholes gambiae mosquito. These methods have been applied to include agricultural pests, disease vectors and nuisance insects (important for many tourist-based economies).